| pubmed-article:16603448 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16603448 | lifeskim:mentions | umls-concept:C0162638 | lld:lifeskim |
| pubmed-article:16603448 | lifeskim:mentions | umls-concept:C2717940 | lld:lifeskim |
| pubmed-article:16603448 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:16603448 | lifeskim:mentions | umls-concept:C1099354 | lld:lifeskim |
| pubmed-article:16603448 | lifeskim:mentions | umls-concept:C0376515 | lld:lifeskim |
| pubmed-article:16603448 | lifeskim:mentions | umls-concept:C2346484 | lld:lifeskim |
| pubmed-article:16603448 | lifeskim:mentions | umls-concept:C1881189 | lld:lifeskim |
| pubmed-article:16603448 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:16603448 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:16603448 | pubmed:dateCreated | 2006-4-10 | lld:pubmed |
| pubmed-article:16603448 | pubmed:abstractText | To investigate the changes in drug sensitivity of Bcl-2 siRNA transfected HepG2 cells. Bcl-2 siRNA and negative siRNA expression vector were constructed and stably transfected into HepG2 cells. RT-PCR and Immunofluorescence were used to detect the target gene expression. Western Blotting was used to detect Bcl-2, Bax and caspase-3 protein expressiom. Drug sensitivity of the cells to 5-fluorouracil (5-FU) and 10-hydroxycamptothecin (HCPT) were analyzed with MTT and flow cytometry. Results were following: (1) the mRNA and protein expression level of Bcl-2 in Bcl-2 siRNA stable transfectants were reduced compared with negative siRNA transfected or untreated cells. Accordingly, Bax protein expression had no change and caspase-3 protein expression showed significantly be up regulated; (2) MTT results showed that Bcl-2 siRNA transfectants had higher cell inhibitory rates after treated with 5-FU or HCPT; (3) flow cytometry results demonstrated that sub G1 population increased in Bcl-2 siRNA transfected cells compared with negative siRNA or untreated cells. After addition 5-FU (1300 mg/l) and HCPT (0.72 mg/l), Bcl-2 siRNA cells showed higher sub G1 population than negative siRNA or untreated cells. siRNA targeting Bcl-2 gene can specifically down-regulate Bcl-2 expression, increased Bax/Bcl-2 ratio expression and caspase-3 activity in HepG2 cells, which lead to increase cells spontaneous apoptosis and sensitize cells to 5-FU or HCPT. Bcl-2 siRNA may be a potential therapy agent against human hepatoblastoma. | lld:pubmed |
| pubmed-article:16603448 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16603448 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603448 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16603448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603448 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16603448 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16603448 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:16603448 | pubmed:issn | 1061-186X | lld:pubmed |
| pubmed-article:16603448 | pubmed:author | pubmed-author:ZhongMiaoM | lld:pubmed |
| pubmed-article:16603448 | pubmed:author | pubmed-author:LiaoDuan-Fang... | lld:pubmed |
| pubmed-article:16603448 | pubmed:author | pubmed-author:LeiXiao-YongX... | lld:pubmed |
| pubmed-article:16603448 | pubmed:author | pubmed-author:ZhuBing-YangB... | lld:pubmed |
| pubmed-article:16603448 | pubmed:author | pubmed-author:FengLan-FangL... | lld:pubmed |
| pubmed-article:16603448 | pubmed:author | pubmed-author:TangSheng-Son... | lld:pubmed |
| pubmed-article:16603448 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16603448 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:16603448 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16603448 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16603448 | pubmed:pagination | 21-6 | lld:pubmed |
| pubmed-article:16603448 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:meshHeading | pubmed-meshheading:16603448... | lld:pubmed |
| pubmed-article:16603448 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16603448 | pubmed:articleTitle | Bcl-2 siRNA induced apoptosis and increased sensitivity to 5-fluorouracil and HCPT in HepG2 cells. | lld:pubmed |
| pubmed-article:16603448 | pubmed:affiliation | Institute of Pharmarcy and Pharmacology, Nanhua University, Hengyang, 421001, China. | lld:pubmed |
| pubmed-article:16603448 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16603448 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16603448 | lld:pubmed |
